Jadranka Bozja

TL;DR: Results reveal that cVLPs designed by incorporating flagellin as a membrane-anchored adjuvant induce enhanced cross-protective heterosubtypic immune responses, and indicate that such cVLP vaccines are a promising new approach for protection against pandemic influenza viruses.

TL;DR: It is demonstrated that an inactivated influenza vaccine supplemented with M2 VLPs prevents disease symptoms without showing weight loss and confers complete cross protection against lethal challenge with heterologous influenza A viruses including the 2009 H1N1 pandemic virus as well as heterosubtypic H3N2 and H5N1 influenza viruses.

TL;DR: This study demonstrates that VLP vaccination provides effective protection against RSV infection by demonstrating higher viral neutralizing antibodies in vitro and significantly decreased lung virus loads in vivo after live RSV-A2 challenge.

TL;DR: Novel HIV virus-like particles presenting a high level of Env in its native membrane-bound form and coincorporating an innate immune-signaling adjuvant in the same particles were effective in inducing enhanced systemic and mucosal immunity.

TL;DR: New light-activated antimicrobial materials with a potentially wide range of possible uses in civilian settings were synthesized by the grafting of protoporphyrin IX and zinc protoporalin IX to nylon fibers, which showed increased antimicrobial activity against S. aureus with increasing exposure time.